Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Disease
PRINCETON, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/dryeye?src=hash" target="_blank"gt;#dryeyelt;/agt;--Oyster Point Pharma raises $93M Series B financing to support the Phase 3 development of the company's investigational treatment for Dry Eye Disease.